Literature DB >> 3566520

Ergometer modification for combined arm-leg use by lower extremity amputees in cardiovascular testing and training.

A G Bostom, E Bates, N Mazzarella, E Block, J Adler.   

Abstract

A commercial arm-leg ergometer was adapted so that combined bilateral arm-single leg work could be performed by unilateral lower extremity amputees from their own wheelchairs. Three middle-aged to elderly unilateral amputees performed progressive discontinuous bilateral arm crank and combined bilateral arm-single leg cycle exercise tests on the same air-braked ergometer adapted for either form of ergometry. Select amputees may achieve greater peak oxygen uptakes (VO2), power outputs (PO), and heart rates (HR) during combined bilateral arm-single leg cycle testing versus bilateral arm crank testing. Following 14 weeks of combined arm-leg training on the modified ergometer, a 73-year-old above-knee amputee demonstrated peak VO2 and PO increases of 25% (+3.8 mL X kg-1 X min-1) and 33% (+25W) respectively. Combined arm-leg ergometry as described herein may activate the largest available muscle mass and elicit the greatest oxygen uptake during exercise testing. In addition this exercise modality may simultaneously condition the arms and leg, providing functional gains in both wheelchair propulsion and prosthetic ambulation.

Entities:  

Mesh:

Year:  1987        PMID: 3566520

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  2 in total

1.  Home-based treadmill training to improve gait performance in persons with a chronic transfemoral amputation.

Authors:  Benjamin J Darter; David H Nielsen; H John Yack; Kathleen F Janz
Journal:  Arch Phys Med Rehabil       Date:  2013-08-13       Impact factor: 3.966

2.  Feasibility, safety, and reliability of exercise testing using the combined arm-leg (Cruiser) ergometer in subjects with a lower limb amputation.

Authors:  Elisabeth K Simmelink; Johan B Wempe; Jan H B Geertzen; Lucas H V van der Woude; Rienk Dekker
Journal:  PLoS One       Date:  2018-08-13       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.